FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118599727> ?p ?o ?g. }

• W3118599727 endingPage "288" @default.
• W3118599727 startingPage "279" @default.
• W3118599727 abstract "A phase 3 study was conducted to verify the efficacy and safety of 5% sofpironium bromide (BBI-4000) gel (hereinafter referred to as sofpironium) administrated for 6 weeks in Japanese patients with primary axillary hyperhidrosis. The primary efficacy end-point was the proportion of patients who satisfied both criteria of a Hyperhidrosis Disease Severity Score (HDSS) of 1 or 2 at the end of 6-week treatment and a 50% or more reduction in total gravimetric weight of sweat at the end of treatment relative to baseline. A total of 281 patients were randomized to receive 5% sofpironium (141 patients) or vehicle (140 patients), and all patients were included in the full analysis set (FAS). In the FAS, 70.1% of patients were female, and the median age was 35.0 years. The proportion of patients who achieved the primary efficacy end-point was 53.9% in the sofpironium group and 36.4% in the vehicle group, with a statistically significant difference of 17.5% (95% confidence interval, 6.02-28.93) between these two groups (P = 0.003). The incidence of adverse events was 44.0% in the sofpironium group and 30.7% in the vehicle group, and the incidence of adverse drug reactions was 16.3% in the sofpironium group and 5.0% in the vehicle group. Reported adverse events were generally mild or moderate in severity. In the sofpironium group, common events (incidence, ≥5%) were nasopharyngitis (14.2%) and dermatitis/erythema at the application site (8.5%/5.7%), with no serious adverse events reported. This study demonstrated the efficacy and safety of 5% sofpironium." @default.
• W3118599727 created "2021-01-18" @default.
• W3118599727 creator A5000565136 @default.
• W3118599727 creator A5001453267 @default.
• W3118599727 creator A5011543234 @default.
• W3118599727 creator A5013118791 @default.
• W3118599727 creator A5018921522 @default.
• W3118599727 creator A5019550971 @default.
• W3118599727 creator A5020185674 @default.
• W3118599727 creator A5040762850 @default.
• W3118599727 creator A5041861970 @default.
• W3118599727 creator A5050849496 @default.
• W3118599727 creator A5051791100 @default.
• W3118599727 creator A5055272715 @default.
• W3118599727 creator A5059748006 @default.
• W3118599727 creator A5059930129 @default.
• W3118599727 creator A5060059025 @default.
• W3118599727 creator A5060808726 @default.
• W3118599727 creator A5062576639 @default.
• W3118599727 creator A5068426528 @default.
• W3118599727 creator A5068542351 @default.
• W3118599727 creator A5071714454 @default.
• W3118599727 creator A5078050241 @default.
• W3118599727 creator A5078256555 @default.
• W3118599727 creator A5081275746 @default.
• W3118599727 creator A5082789874 @default.
• W3118599727 creator A5083877410 @default.
• W3118599727 creator A5091502852 @default.
• W3118599727 date "2021-01-07" @default.
• W3118599727 modified "2023-10-11" @default.
• W3118599727 title "A phase 3, multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis" @default.
• W3118599727 cites W1995163833 @default.
• W3118599727 cites W2037537994 @default.
• W3118599727 cites W2038915663 @default.
• W3118599727 cites W2068133922 @default.
• W3118599727 cites W2075375851 @default.
• W3118599727 cites W2085727869 @default.
• W3118599727 cites W2091724706 @default.
• W3118599727 cites W2096991001 @default.
• W3118599727 cites W2106475808 @default.
• W3118599727 cites W2116752342 @default.
• W3118599727 cites W2170874530 @default.
• W3118599727 cites W2465799764 @default.
• W3118599727 cites W2601511492 @default.
• W3118599727 cites W2794564462 @default.
• W3118599727 cites W2812196991 @default.
• W3118599727 cites W2911960068 @default.
• W3118599727 cites W2967103828 @default.
• W3118599727 cites W2982867557 @default.
• W3118599727 cites W399422828 @default.
• W3118599727 cites W4362204579 @default.
• W3118599727 doi "https://doi.org/10.1111/1346-8138.15668" @default.
• W3118599727 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7986147" @default.
• W3118599727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33410265" @default.
• W3118599727 hasPublicationYear "2021" @default.
• W3118599727 type Work @default.
• W3118599727 sameAs 3118599727 @default.
• W3118599727 citedByCount "11" @default.
• W3118599727 countsByYear W31185997272021 @default.
• W3118599727 countsByYear W31185997272022 @default.
• W3118599727 countsByYear W31185997272023 @default.
• W3118599727 crossrefType "journal-article" @default.
• W3118599727 hasAuthorship W3118599727A5000565136 @default.
• W3118599727 hasAuthorship W3118599727A5001453267 @default.
• W3118599727 hasAuthorship W3118599727A5011543234 @default.
• W3118599727 hasAuthorship W3118599727A5013118791 @default.
• W3118599727 hasAuthorship W3118599727A5018921522 @default.
• W3118599727 hasAuthorship W3118599727A5019550971 @default.
• W3118599727 hasAuthorship W3118599727A5020185674 @default.
• W3118599727 hasAuthorship W3118599727A5040762850 @default.
• W3118599727 hasAuthorship W3118599727A5041861970 @default.
• W3118599727 hasAuthorship W3118599727A5050849496 @default.
• W3118599727 hasAuthorship W3118599727A5051791100 @default.
• W3118599727 hasAuthorship W3118599727A5055272715 @default.
• W3118599727 hasAuthorship W3118599727A5059748006 @default.
• W3118599727 hasAuthorship W3118599727A5059930129 @default.
• W3118599727 hasAuthorship W3118599727A5060059025 @default.
• W3118599727 hasAuthorship W3118599727A5060808726 @default.
• W3118599727 hasAuthorship W3118599727A5062576639 @default.
• W3118599727 hasAuthorship W3118599727A5068426528 @default.
• W3118599727 hasAuthorship W3118599727A5068542351 @default.
• W3118599727 hasAuthorship W3118599727A5071714454 @default.
• W3118599727 hasAuthorship W3118599727A5078050241 @default.
• W3118599727 hasAuthorship W3118599727A5078256555 @default.
• W3118599727 hasAuthorship W3118599727A5081275746 @default.
• W3118599727 hasAuthorship W3118599727A5082789874 @default.
• W3118599727 hasAuthorship W3118599727A5083877410 @default.
• W3118599727 hasAuthorship W3118599727A5091502852 @default.
• W3118599727 hasBestOaLocation W31185997272 @default.
• W3118599727 hasConcept C120665830 @default.
• W3118599727 hasConcept C121332964 @default.
• W3118599727 hasConcept C126322002 @default.
• W3118599727 hasConcept C141071460 @default.
• W3118599727 hasConcept C168563851 @default.
• W3118599727 hasConcept C197934379 @default.
• W3118599727 hasConcept C203092338 @default.
• W3118599727 hasConcept C2778650131 @default.
• W3118599727 hasConcept C2779121184 @default.

• next